Trial Profile
Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine, Formulation 2011-2012, in Non-Elderly Adult and Elderly Subjects
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors Adimmune Corporation
- 11 Jul 2012 Actual end date (Mar 2012) added as reported by ClinicalTrials.gov.
- 01 Mar 2012 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
- 05 Aug 2011 New trial record